Provided by Tiger Trade Technology Pte. Ltd.

Biomea Fusion, Inc.

1.73
+0.14008.81%
Post-market: 1.750.0200+1.16%19:56 EDT
Volume:4.46M
Turnover:7.62M
Market Cap:125.08M
PE:-3.67
High:1.81
Open:1.63
Low:1.58
Close:1.59
52wk High:2.99
52wk Low:0.8719
Shares:72.30M
Float Shares:67.01M
Volume Ratio:1.55
T/O Rate:6.65%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4711
EPS(LYR):-1.1832
ROE:-164.14%
ROA:-63.46%
PB:10.31
PE(LYR):-1.46

Loading ...

Biomea Fusion announces positive 52-week results from phase 2 COVALENT-112 trial

TIPRANKS
·
Apr 28

Biomea Fusion says icovamenib boosts C-peptide in 52-week Phase 2 type 1 diabetes trial

Reuters
·
Apr 28

Biomea Fusion Inc: Icovamenib Was Generally Well Tolerated, With No New or Unexpected Safety Signals Identified Throughout 52-Week Observation Period

THOMSON REUTERS
·
Apr 28

Biomea Fusion Announces Positive 52-Week Results From Phase 2 Covalent-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment

THOMSON REUTERS
·
Apr 28

Biomea Fusion Inc: Based on Data Co Is Planning Phase 2 Trial in Collaboration With 4 U.S. Academic Centers

THOMSON REUTERS
·
Apr 28

Biomea Fusion announces annual shareholder meeting

Reuters
·
Apr 28

Biomea Fusion Advances Mid‑Stage Diabetes Trial, Adding a New Angle to the BMEA Investment Story

TIPRANKS
·
Apr 09

Biomea Fusion Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Apr 08

Biomea Fusion Inc: Topline 26-Week Primary Endpoint Data From Both Phase Ii Studies Anticipated 4Q 2026

THOMSON REUTERS
·
Mar 31

Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies

GlobeNewswire
·
Mar 31

Biomea Fusion Is Maintained at Buy by Citigroup

Dow Jones
·
Mar 27

Citi ups Biomea Fusion target, adds ‘upside 90-day catalyst watch’

TIPRANKS
·
Mar 27

Biomea Fusion Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Mar 26

Biomea Fusion Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Mar 25

Analysts Are Bullish on These Healthcare Stocks: Alnylam Pharma (ALNY), Biomea Fusion (BMEA)

TIPRANKS
·
Mar 25

Analysts Offer Insights on Healthcare Companies: BioNTech SE (BNTX) and Biomea Fusion (BMEA)

TIPRANKS
·
Mar 25

Biomea Fusion Q4 EPS $0.27 Beats $(0.23) Estimate

Benzinga Earnings
·
Mar 25

Press Release: Biomea Fusion Reports Full Year 2025 Financial Results and Corporate Highlights

Dow Jones
·
Mar 25

Biomea Fusion presents Phase II Covalent-111 data in Type 2 Diabetes

TIPRANKS
·
Mar 15

Biomea Fusion reports Phase II COVALENT-111 data showing 1% HbA1c reduction at Week 52 with icovamenib in type 2 diabetes patients

Reuters
·
Mar 14